Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...

New study from University of California, Irvine and University of California, Santa Barbara researchers demonstrates improved retinal function and vascular integrity, supporting further investigation ...

Santen Pharmaceutical has signed a licensing agreement with RemeGen for the RC28-E intravitreal injection, a dual-target fusion protein designed to treat retinal diseases. The agreement, facilitated ...

TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD ® ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron ...

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual ...

(MENAFN- GlobeNewsWire - Nasdaq) New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase ...